HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients

✍ Scribed by Altundag, Ozden; Altundag, Kadri; Ozcakar, Bulent; Silay, Yavuz S.

• Book ID: 119319175
• Publisher: Elsevier Science
• Year: 2005
• Tongue: English
• Weight: 55 KB
• Volume: 49
• Category: Article
• ISSN: 0169-5002
• DOI: 10.1016/j.lungcan.2005.02.013